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Is There Any Light at the End of the Catheter?*Sanjay Kaul, MD,yz Jagat Narula, MD, PHDxSEE PAGE 2510P laque destabilization with consequent rupture(or erosion) and superimposed thrombosis isthe proximate cause of acute coronary syn-
dromes (ACS). Although ACS treatment has advanced
considerably in the past decade, the ability to detect,
predict, and prevent plaque vulnerability remains
elusive.
Several imaging tools have been developed to
characterize morphological determinants of plaque
vulnerability (1). Among these, intravascular ultra-
sound (IVUS) is useful for characterizing stenosis
severity, plaque burden (PB), remodeling, and calci-
ﬁcation but has low resolution and limited ability
to detect plaque erosion, rupture, and thrombus.
Optical coherence tomography (OCT) can characterize
plaques but possesses poor penetration, thereby
limiting assessment of PB and overall plaque volume,
and inadequate ability to characterize plaque com-
position beyond lipid deposits. Although OCT may
deﬁne plaque rupture, thrombus, and thin cap, it
requires a bloodless ﬁeld and currently lacks a fully
automated and validated method for detecting lipid
components. Near-infrared spectroscopy (NIRS)
identiﬁes the chemical signature of the lipid compo-
nent, speciﬁcally lipid core-containing coronary pla-
que (LCP), but provides no information on the lumen,
plaque anatomy, and status of the ﬁbrous cap or its
attenuation. OCT and NIRS can image through*Editorials published in the Journal of the American College of Cardiology
reﬂect the views of the authors and do not necessarily represent the
views of JACC or the American College of Cardiology.
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paper to disclose.calciﬁed lesions, whereas IVUS cannot. Given that
progression of coronary atherosclerosis depends on
multiple factors that are cumulative, interactive, and
nonlinear, a single imaging technique is unlikely to
reliably detect all vulnerable plaques and predict
outcomes.The TVC NIRS imaging system (Infraredx, Inc.,
Burlington, Massachusetts) is an intravascular
imaging tool with 510(k) Food and Drug Administra-
tion clearance for LCP detection. In this issue of
the Journal, Oemrawsingh et al. (2) present the
results of the ATHEROREMO-NIRS study, part of the
ATHEROREMO (European Collaborative Project on
Inﬂammation and Vascular Wall Remodeling in
Atherosclerosis) study. This single-center substudy is
the ﬁrst prospective, observational, natural history
study designed to evaluate the prognostic implica-
tions of NIRS-detected increased lipid content in
coronary plaques. Investigators analyzed data for 203
patients who underwent coronary angiography and
percutaneous coronary intervention (PCI), if indi-
cated, of the target lesion, and NIRS assessment in a
nonculprit coronary segment. During 1-year follow-
up, 28 sustained a major adverse cardiac and cere-
brovascular event (MACCE), including 21 nonculprit
lesion (NCL)–related events. Lipid core burden
index (LCBI), as assessed by NIRS, independently
predicted MACCE. The investigators acknowledge
important study strengths and limitations. One
notable limitation not addressed is whether LCBI
offered incremental prognostic utility beyond the
clinical variables of history of stroke and peripheral
artery disease that were associated with MACCE.
They appropriately characterize their ﬁndings as
hypothesis-generating given that results from any
single-center study, no matter how robust, must be
replicated to be accepted.
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Over the past decade, several prospective longitudi-
nal studies utilizing intravascular imaging tools have
yielded substantial insights into the natural history of
culprit lesion formation (3–6) (Table 1). These trials
have evaluated catheter-based plaque assessment for
conﬁrmation and secondary screening after symp-
tomatic patient presentation. There are important
differences among the trials in terms of patient pop-
ulation studied: ACS versus stable coronary artery
disease (CAD), number of coronary vessels assessed
(1 vs. 3), deﬁnition of large PB or thin-cap ﬁbroa-
theroma (TCFA), outcome measures of major adverse
cardiac events (MACE, different deﬁnitions), and
reporting of lesion- or patient-speciﬁc outcomes.
Thus, while their results cannot be directly compared,
these studies have added to our understanding of
the determinants of plaque vulnerability.
Table 2 summarizes the prognostic performance of
currently available intravascular imaging tools for
plaque phenotyping (PB or composition) in predicting
MACE. For comparison, data also are shown for
noninvasive coronary computed tomographic angi-
ography (CTA) (7) and intracoronary fractional ﬂow
reserve (FFR) assessment (8). Although all lesion
characteristics were signiﬁcantly associated with
outcomes (except for minimum lumen area
[MLA] #4.0 mm2 in the ATHEROREMO-IVUS study
[6]), the positive predictive value (PPV) ranged from
4% for TCFA in the PROSPECT (Providing Regional
Observations to Study Predictors of Events in the
Coronary Tree) trial to 19% for PB >70%, also in the
PROSPECT trial, reﬂecting the low prevalence (pre-
test likelihood) of outcomes (3). The C index, the only
metric independent of prevalence, tracked with other
outcomes with PB >70% in the PROSPECT trial
yielding the highest discrimination (area under the
curve [AUC]: 0.82). Lesions exhibiting all 3 IVUS-
deﬁned correlates of vulnerability (PB >70% þ
MLA #4.0 mm2 þ TCFA) yielded the highest hazard
ratio (HR) and AUC for predicting future NCL-related
events. However, the PPV was only 18% to 23%,
reﬂecting MACE’s low prevalence. Notably, NIRS-
determined LCP, a measure of plaque necrotic core
without PB, had comparable prognostic utility for
MACE compared with all 3 IVUS-deﬁned characteris-
tics combined in the ATHEROREMO-IVUS study (HR:
4.2 vs. 3.7; PPV: 17% vs. 23%; AUC: 0.74 vs. 0.72).
Furthermore, the predictive value of LCP for the
occurrence of nonrevascularization MACE (composite
of death, ACS, or stroke) or acute cardiac events
(cardiac death or nonfatal ACS) was even stronger
(unadjusted HR: 11.9 and 9.4; AUC: 0.85 and 0.82,
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2522respectively). In the PREDICTION (Prediction of Pro-
gression of Coronary Artery Disease and Clinical
Outcome Using Vascular Proﬁling of Shear Stress and
Wall Morphology) trial, large plaque size and low
endothelial shear stress independently predicted the
exploratory endpoint of worsening of luminal ob-
structions treated with PCI at follow-up (PPV of 42%
and negative predictive value of 92% for combined
variables) (5).
From these trial data, one can reasonably conclude
that large PB alone or in combination with other lesion
characteristics is predictive for future NCL-related
MACE compared with other plaque characteristics.
This was ﬁrst observed in the PROSPECT study, later
conﬁrmed in other studies (4,6), and is consistent
with the observation that these lesions are more likely
to progress, compromise lumen, and become ﬂow-
limiting, eventually resulting in ischemic symptoms
requiring revascularization or even acute events.
Accordingly, among the 2,157 patients evaluated
collectively in these 5 trials, revascularization (7.37%)
and hospitalizations for worsening angina (3.66%)
occurred most frequently; however, the incidence of
hard outcomes such as cardiovascular (CV) deaths
(0.65%) or myocardial infarction (MI)/unstable angina
(1.25%) was too low to assess reliably the prognostic
utility of vulnerable plaque.
In contrast, positively remodeled coronary seg-
ments with low attenuation plaque on CTA had rela-
tively higher prognostic utility for ACS events (odds
ratio: 45.6; PPV: 22%; AUC: 0.95) (7). Similar to
intravascular plaque imaging, prognostic utility for
FFR #0.80 was conﬁned to revascularization in
medically treated patients with stable CAD (8).
Several reasons explain the rather modest prog-
nostic utility of NIRS-identiﬁed vulnerable plaque
characteristics in this study. First, the LCP threshold
utilized was not AUC-derived but based on median
values. Although only 25% of patients had LCBI >90,
even much higher thresholds utilized in other studies
have produced mixed results for prognostic utility.
For example, maxLCBI4mm $500 was associated with
PPV of 50% and AUC of 0.90 for periprocedural MI
in the COLOR registry (9), a prospective multicenter
observational study of patients undergoing NIRS.
However, maxLCBI4mm $600 in the CANARY (Coro-
nary Assessment by Near-infrared of Atherosclerotic
Rupture-prone Yellow) trial failed to support the
role of ﬁlter devices to protect against periprocedural
MI (10). Second, given the lack of repeat NIRS eval-
uation before the recurrent event, a possible dynamic
transition in plaque morphology prior to rupture
might have been missed. Third, inﬂammatory cell
inﬁltrate, a hallmark of vulnerable plaque, cannot bedetected by NIRS (or IVUS). Fourth, not all
ruptured plaques result in a clinical CV event; some
plaques rupture and then become quiescent, healing
without causing MI or ischemic symptoms. Similarly,
not all acute CV events result from plaque rup-
ture because nonruptured plaques have been impli-
cated as culprit lesions nearly one-third of the time in
autopsy series (11) and in a recent OCT study in ACS
(12). Fifth, future culprit lesions located in other ves-
sels (only 1 vessel assessed for LCP per patient) or in
distal segments of evaluated vessels were inaccessible
to NIRS. Sixth, aggressive secondary prevention ef-
forts instituted in this study might have mitigated the
risk of plaque rupture resulting in too few “hard”
clinical events (cardiac death or MI) to assess reliably
the prognostic utility of vulnerable plaque. Finally,
other factors, such as systemic coagulability, local
thrombogenicity, and vascular tone, also contribute to
the outcome of plaque disruption.
IMPLICATIONS
Adoption of imaging tools to detect plaque vulnera-
bility in clinical practice should ideally be based on 3
key criteria: 1) prospective validation of plaque
characteristics as an independent predictor of future
CV events (“prognostic” utility); 2) establishment of
added prognostic utility (preferably based on change
in discrimination or risk classiﬁcation) on top of
currently available or less invasive methods of risk
stratiﬁcation (“incremental” utility); and 3) demon-
stration that detection would alter treatment
decisions leading to improved outcomes in a cost-
effective manner (“predictive” or clinical utility). It
is debatable whether NIRS (or, for that matter, any
other imaging tool) fulﬁlls all 3 criteria. Furthermore,
the relatively low PPV of plaque characteristics is
driven by the low prevalence of cardiovascular dis-
ease (CVD) in the screened population, thereby
making these tools less desirable in primary versus
secondary prevention settings.
Other lingering questions remain about NIRS and
other imaging tools.
1. Can pre-emptive, focal treatment of invasively
detected vulnerable plaques be accomplished in
a safe, efﬁcacious, and cost-effective manner?The quest for vulnerable plaque is predicated on
the postulate that intervention might preclude
plaque destabilization and thrombosis, possibly
preventing ACS. Pilot studies have demonstrated
the feasibility and safety of plaque “passivation” or
“sealing” (13,14). This concept will be explored in
the PROSPECT II trial in conjunction with NIRS
imaging utilizing bioresorbable scaffold technology.
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25232. Should systemic secondary prevention strategies
be tailored based on detection of vulnerable
plaques?A pilot study, YELLOW (Reduction in YEllow Pla-
que by Aggressive Lipid LOWering Therapy),
showed improvement in plaque composition (LCBI
measurement with NIRS) within 7 weeks of high-
dose (40 mg daily) rosuvastatin in severely
obstructed stenosis (FFR <0.80) versus standard
statin therapy (15). However, the recently pub-
lished results of the IBIS-4 (Integrated Biomarker
and Imaging Study-4) study showed modest, but
statistically signiﬁcant, evidence of plaque
regression without change in plaque composition
(percent necrotic burden or ﬁbrofatty atheromas)
or phenotype (TCFA) in nonobstructed noninfarct
lesions in response to high-intensity therapy with
rosuvastatin 40 mg among ST-segment elevation
MI patients (16). These ﬁndings raise questions
regarding the predictive utility of NIRS in an
ongoing study (17). Perhaps combining strategies
that detect PB (IVUS), ﬁbrous cap thickness (OCT),
and plaque composition (NIRS), along with sys-
temic markers of inﬂammation, might improve
prognostic and predictive utility making this
approach more clinically useful.
3. Can the ﬁndings from imaging tools be used to
guide drug development?The IBIS-2 study showed that the lipoprotein-
associated phospholipase A2 inhibitor darapladib
halted necrotic core expansion in patients withACS and stable CAD compared with the expan-
sion of the necrotic core in the placebo group
despite a high-level standard of care treatment
(18). However, large-scale randomized trials with
darapladib produced no outcome beneﬁt, raising
questions about the suitability of assessing dy-
namic changes in plaque composition alone
to predict outcome beneﬁt with therapeutic
interventions (19,20).
4. Will a global risk score that integrates clinical,
angiographic, and plaque characteristics with
genetic and serum biomarkers improve the ac-
curacy of our clinical predictions?This remains to be determined in ongoing pro-
spective trials such as the LRP (Lipid-Rich Plaque)
study, the PROSPECT II study, and the main
ATHEROREMO study.
These questions will need to be answered un-
equivocally before detection of vulnerable plaque by
NIRS, or other invasive or noninvasive imaging tool,
can be recommended for the prevention and treat-
ment of CVD, and several trials are underway to solve
those puzzles. Until then, the intravascular imaging
modalities remain just another tool for research.
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